Aurobindo Pharma moves up as its arm gets US FTC's approval to acquire Lannett
Aurobindo Pharma is currently trading at Rs. 1505.65, up by 7.80 points or 0.52% from its previous closing of Rs. 1497.85 on the BSE.
The scrip opened at Rs. 1494.15 and has touched a high and low of Rs. 1,510.00 and Rs. 1494.15 respectively. So far 491 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1550.00 on 21-May-2026 and a 52 week low of Rs. 1017.00 on 02-Sep-2025.
Last one week high and low of the scrip stood at Rs. 1,510.00 and Rs. 1391.40 respectively. The current market cap of the company is Rs. 86182.98 crore.
The promoters holding in the company stood at 51.82%, while Institutions and Non-Institutions held 41.11% and 7.08% respectively.
Aurobindo Pharma’s wholly owned subsidiary -- Aurobindo Pharma USA, Inc. (Aurobindo USA) has received approval from the U.S. Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC (Lannett). The transaction, valued at $250 million on a cash-free, debt-free basis and inclusive of normalized working capital, is expected to close before the end of June 2026.
Lannett, a Pennsylvania-based generic pharmaceutical company, specializes in the development and commercialization of a diversified portfolio of complex, non-opioid controlled substances. The acquisition will significantly expand Aurobindo USA’s product offering in this segment while adding a U.S.-based manufacturing facility to its network. Lannett’s manufacturing site in Seymour, Indiana, has the capacity to scale production to around 4 billion doses annually, strengthening Aurobindo USA’s domestic manufacturing footprint. This enhanced capacity aligns with U.S. policy priorities aimed at improving supply chain resilience and increasing domestic pharmaceutical production.
The transaction is expected to be immediately accretive to Aurobindo Group’s earnings per share. In addition to near-term financial benefits, the acquisition is anticipated to generate meaningful cost efficiencies, SG&A synergies, and operational integration advantages. It will also enhance the company’s portfolio with a differentiated pipeline of complex generics and controlled substances, supporting sustainable long-term growth.
.jpg)
